NCT04387071 2026-04-17
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
University of Southern California
Phase 1/2 Terminated
Clinical Trials
18 trialsNCT07444541 2026-04-16
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Phase 1/2 Not yet recruiting
NCT06799637 2026-04-15
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Evopoint Biosciences Inc.
Phase 1/2 Recruiting
NCT07353645 2026-04-15
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Recruiting
NCT07529808 2026-04-15
ChefHat-001
BigHat Biosciences, Inc.
Phase 1/2 Not yet recruiting
NCT04172532 2026-04-13
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05053971 2026-04-13
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT07223047 2026-04-13
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT02830724 2026-04-06
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT07020221 2026-04-03
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Recruiting
NCT06710132 2026-04-02
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
EMD Serono
Phase 1/2 Recruiting
NCT06445062 2026-04-01
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT06483555 2026-04-01
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07504263 2026-03-31
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Recurv Pharma Inc
Phase 1/2 Not yet recruiting
NCT05586516 2026-03-30
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
Phase 1/2 Completed
NCT05039177 2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2 Completed